300 related articles for article (PubMed ID: 14747421)
1. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
[TBL] [Abstract][Full Text] [Related]
2. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
Wang J; Zeevi A; McCurry K; Schuetz E; Zheng H; Iacono A; McDade K; Zaldonis D; Webber S; Watanabe RM; Burckart GJ
Transpl Immunol; 2006 Jan; 15(3):235-40. PubMed ID: 16431292
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
4. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
6. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
7. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
8. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
Zheng HX; Zeevi A; McCurry K; Schuetz E; Webber S; Ristich J; Zhang J; Iacono A; Dauber J; McDade K; Zaldonis D; Lamba J; Burckart GJ
Transpl Immunol; 2005 Mar; 14(1):37-42. PubMed ID: 15814280
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms.
Zheng H; Webber S; Zeevi A; Schuetz E; Zhang J; Bowman P; Boyle G; Law Y; Miller S; Lamba J; Burckart GJ
Am J Transplant; 2003 Apr; 3(4):477-83. PubMed ID: 12694072
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
Li D; Gui R; Li J; Huang Z; Nie X
Transplant Proc; 2006 Nov; 38(9):2850-2. PubMed ID: 17112846
[TBL] [Abstract][Full Text] [Related]
16. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements.
Fredericks S; Jorga A; MacPhee IA; Reboux S; Shiferaw E; Moreton M; Carter ND; Holt DW; Johnston A
Clin Transplant; 2007; 21(2):252-7. PubMed ID: 17425754
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements.
Fredericks S; Moreton M; Reboux S; Carter ND; Goldberg L; Holt DW; MacPhee IA
Transplantation; 2006 Sep; 82(5):705-8. PubMed ID: 16969296
[TBL] [Abstract][Full Text] [Related]
18. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
